Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1128.7000 -1.60 (-0.14%)
NSE Oct 13, 2025 12:21 PM
Volume: 1.0M
 

1128.70
-0.14%
Axis Direct
US Sales (44% of sales) grew 9% YoY on new launches, but declined 9% QoQ (given increasing competition in gRenvela). Sales growth across other key verticals was strong (EU: up 37% YoY, RoW: up 33% YoY) which led to 15% YoY growth in EBITDA.
Aurobindo Pharma Ltd. is trading above its 150 day SMA of 1128.6
More from Aurobindo Pharma Ltd.
Recommended